Evidence map›Paper›PMID 34790784›Full record

ArticleAnnals of translational medicine2021

Jinyan Yuan, Xiao Liang, Wei Zhou, Jing Feng, Zhenyang Wang, Shaoxian Shen, Xin Guan, Liangbin Zhao, Fei Deng

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Research Progress on TRPA1 in Diseases.The Journal of membrane biology · 2023
    Review
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jinyan Yuan *Department of Nephrology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Xiao Liang *Department of Internal Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Wei Zhou *School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Jing FengDepartment of Traditional Chinese Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Zhenyang WangDepartment of Nephrology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Shaoxian ShenDepartment of Nephrology, Jinniu Hospital of Sichuan Provincial People's Hospital and Chengdu Jinniu District People's Hospital, Chengdu, China.
Xin GuanDepartment of Nephrology, Jinniu Hospital of Sichuan Provincial People's Hospital and Chengdu Jinniu District People's Hospital, Chengdu, China.
Liangbin ZhaoDepartment of Nephrology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Fei DengDepartment of Nephrology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital · CNUniversity of Electronic Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe nephrotoxicity induced by cisplatin (DDP) has been a severe obstacle for its clinical use in anticancer treatment. The apoptosis and inflammation induced by DDP are the main causes of the nephrotoxicity. Transient receptor potential ankyrin 1 (

methodsThe apoptosis, inflammation, MAPK/NF-κB signaling pathway, and

resultsThe cell viability was reduced by DDP in both a time-dependent and dose-dependent manner with a minimal cytotoxic concentration of 10 μM. Moreover, DDP induced an enhancement of the apoptosis and inflammation in a dose-dependent manner, as indicated by the increase of the relative protein level of cleaved-caspase3 (cleaved-cas3), the cleavage product of caspase-3 substrate poly-ADP-ribose polymerase (cleaved-PARP) and inducible nitric oxide synthase (iNOS), and the messenger RNA (mRNA) expression level of interleukin (

conclusionsTaken together, these results indicate that

Indexed as

apoptosisCisplatin (DDP)MAPK/NF-κB signaling pathwaynephrotoxicitytransient receptor potential ankyrin 1 (TRPA1)

Identifiers

PMID34790784
PMCPMC8576655
OpenAlexW3208043106

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.